Biopharma happenings, including deals and partnerships, and other news in brief: AAX, Avenue, Axsome, Astrazeneca, Baergic, Cue, Dynavax, Expert, Immunoscape, Mwyngil, Tevogen, Toxotech, Vaxart.
Clinical updates, including data readouts and publications: 4D Molecular, Alligator, Bluewillow, Celldex, Eli Lilly, Heidelberg, Hope, Noema, Plus, Rein, Treos, Vera and Viking.
Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody, mezagitamab (TAK-079), sustained kidney function up to 18 months after treatment ended in patients with primary immunoglobulin A (IgA) nephropathy, showing early signs of disease modification in a phase Ib study presented at the American Society of Nephrology’s Kidney Week 2025 in Houston.
Biopharma financings from January through October 2025 totaled $61.45 billion, roughly in line with the $61.04 billion raised during the same period in 2023 but down sharply from last year’s $93.83 billion.
Blocking progesterone receptor (PR) activity has long been viewed as a possible approach to breast cancer prevention. Historically, most supporting evidence came from animal models, epidemiological studies or mechanistic pathway analyses. Now, a team at the University of Manchester has uncovered direct mechanistic and clinical evidence that PR antagonists can reprogram the breast tissue microenvironment, suggesting a novel avenue for reducing breast cancer risk in women.
RSS
